ZYTIGA(R) (abiraterone acetate) Plus Prednisone Approved for Treatment of Earlier Form of Metastatic Prostate Cancer

New indication for ZYTIGA® in combination with prednisone provides treatment option for patients with metastatic high-risk castration-sensitive prostate cancer Findings from pivotal Phase 3 LATITUDE clinical trial data demonstrated statistically sig... Biopharmaceuticals, Oncology, FDA Janssen Pharmaceutical, ZYTIGA, abiraterone, prostate cancer
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news

Related Links:

Condition:   Low Risk Prostate Cancer Intervention:   Drug: TOOKAD VTP Sponsors:   Steba Biotech S.A.;   International Drug Development Institute;   PrimeVigilance LTD Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Initial concerns that finasteride could increase risk of prostate cancer death have been found to be unwarranted in a long-term follow-up study.
Source: Clinical Pharmacist - Category: Drugs & Pharmacology Source Type: research
CONCLUSION: MRI-TRUS guided prostate biopsy improves the detection of PCa, but systematic biopsy is still essential. In selected cases (PIRADS 5), contralateral lobe systematic biopsy can safely be avoided. Pre-biopsy mpMRI might reduce the number of biopsy sessions in patients with anterior and transitional lesions. PMID: 30779829 [PubMed - in process]
Source: Medical Ultrasonography - Category: Radiology Tags: Med Ultrason Source Type: research
The results of the double-blind, phase III trial were presented at the 2019 ASCO Genitourinary Cancers Symposium.
Source: CancerNetwork - Category: Cancer & Oncology Authors: Source Type: news
CONCLUSIONS: This study demonstrated that miR-492 was over-expressed in PCa and exerted tumor-promoting function in PCa cells via repressing SOCS2 expression. This might provide a new sight for future accurate therapy for PCa. PMID: 30779065 [PubMed - in process]
Source: European Review for Medical and Pharmacological Sciences - Category: Drugs & Pharmacology Tags: Eur Rev Med Pharmacol Sci Source Type: research
Hope et al.1 report on the impact of pretreatment 68Ga-PSMA-PET/CT or PET/MRI in the management of 45 patients with high-risk prostate cancer (PCA). Results of PSMA-PET/CTs were compared to the findings of CT scans and skeletal scintigraphy. Based on their data, PSMA-PET imaging resulted in changes of radiation therapy (RT) dose and volumes in 47% of the patients due to newly diagnosed N1/M1a disease. RT changes resulted in the extension of clinical target volume (CTV) covering the small pelvis and even the retroperitoneum or a RT boost to avid lymph nodes.
Source: Urology - Category: Urology & Nephrology Authors: Source Type: research
ConclusionssRP was safe, feasible, and effective using either an open or robot-assisted approach, in experienced hands. Age, preoperative clinical stage, NS procedure, and pathological GS were linked with BCR after sRP.
Source: World Journal of Urology - Category: Urology & Nephrology Source Type: research
ConclusionsAbsolute quantitative223Ra SPECT imaging appears feasible once the dimension of the target is determined. Further evaluation should be needed to apply the calibration factor-based quantitation to clinical223Ra SPECT/CT imaging. This will open the possibility for patient-specific223Ra treatment planning and therapeutic outcome prediction in patients.
Source: EJNMMI Research - Category: Radiology Source Type: research
Expanding genetic testing beyond current guidelines could better stratify prostate cancer patients for the presence of pathogenic variants and improve their medical management, researchers say.Reuters Health Information
Source: Medscape Pathology Headlines - Category: Pathology Tags: Hematology-Oncology News Source Type: news
The combination of ipilimumab with nivolumab shows activity in advanced disease.Medscape Medical News
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news
More News: Abiraterone Acetate | Cancer | Cancer & Oncology | Clinical Trials | Pharmaceuticals | Prednisone | Prostate Cancer | Statistics